Published in final edited form as:

Metallomics. 2015 August ; 7(8): 1256–1264. doi:10.1039/c5mt00028a.

Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents†

Sarah Theiner^{a,b}, Christoph Kornauth^c, Hristo P. Varbanov^a, Markus Galanski^a, Sushilla Van Schoonhoven^{b,d}, Petra Heffeter^{b,d}, Walter Berger^{b,d}, Alexander E. Egger^{*,e}, and Bernhard K. Keppler^{a,b}

^aInstitute of Inorganic Chemistry, University of Vienna, Vienna, Austria

^bResearch Platform 'Translational Cancer Therapy Research', University of Vienna, Vienna, Austria

^cInstitute of Clinical Pathology, Medical University of Vienna, Vienna, Austria

^dInstitute of Cancer Research, Department of Medicine I and Comprehensive Cancer Center of the Medical University, Medical University of Vienna, Vienna, Austria

^eADSI – Austrian Drug Screening Institute GmbH, Innrain 66a, 6020-Innsbruck, Austria

Abstract

The selection of drug candidates for entering clinical development relies on *in vivo* testing in (solid) tumor animal models. However, the heterogeneity of tumor tissue (*e.g.* in terms of drug uptake or tissue composition) is rarely considered when testing novel drug candidates. Therefore, we used the murine colon cancer CT-26 tumor model to study the spatially-resolved drug distribution in tumor tissue upon repetitive treatment of animals over two weeks with three investigational platinum(IV)-based anticancer agents, oxaliplatin or satraplatin. A quantitative laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) imaging method revealed a heterogeneous platinum distribution, which correlated well with the histologic features of the tumor and surrounding tissue at the microscopic level. In most of the cases, higher amounts of intratumoral platinum were found in the surrounding tissue than in the malignant parts of the sample. This indicates that determination of average platinum amounts (*e.g.* by microwave-assisted digestion of the sample followed by analysis with ICP-MS) might overestimate the drug uptake in tumor tissue causing misleading conclusions. In addition, we studied the platinum distribution in the kidneys of treated animals to probe if accumulation in the cortex and medulla predict potential nephrotoxicity. A 10-fold increase of platinum in the cortex of the kidney over the medulla was observed for oxaliplatin and satraplatin. Although these findings are similar to those in the platinum distribution of the nephrotoxic anticancer drug cisplatin, treatment with the compounds of our study did not show signs of nephrotoxicity in clinical use or clinical trials (oxaliplatin, satraplatin) and did not result in the alteration of renal structures. Thus, predicting the side effects based on bioimaging data by LA-ICP-MS should be considered with caution. To the best of our knowledge, this is the first LA-ICP-MS study on spatially-resolved platinum

accumulation in tissues after repetitive platinum-based anticancer drug treatment of mice bearing a preclinical tumor model.

Introduction

Chemotherapy for cancer treatment frequently includes one of the worldwide-approved platinum(II)-based compounds (cisplatin, carboplatin or oxaliplatin).¹ In the last few decades, effort has been made to develop novel platinum(IV)-based cytostatics (*e.g.* tetraplatin, iproplatin and satraplatin) with a focus on the reduction of side effects, overcoming the resistance occurring in platinum(II)-based drug treatment and improvement of oral bioavailability.^{2–4} Platinum(IV) complexes can exert high kinetic inertness in substitution reactions, assuming their stability in the gastrointestinal tract (GIT) and in the blood-stream. ⁵ A prerequisite for their anticancer activity is the formation of the active platinum(II) species upon two-electron reduction preferably in the hypoxic tumor tissue (prodrug-concept).⁶ Therefore, platinum(IV) complexes could be considered as an orally applicable, safe alternative over the established platinum(II)-based chemotherapeutics.^{6,7} Satraplatin ((OC-6-43)-bis(acetato)amminedichlorido(cyclohexylamine)platinum(IV)) has been the first orally active platinum-based drug evaluated in clinical trials.⁸ Despite positive results against refractory prostate cancer, after completion of clinical phase III trial, satraplatin was not approved by the FDA, as it failed to demonstrate decisive benefits with regard to the survival rate.^{9,10}

To gain information on the *in vivo* properties of novel drugs, animal models are widely used to investigate their toxicological profile, pharmacokinetic behavior and therapeutic efficacy.^{11–13} Based on these data, the most promising drug candidates are then selected for further (pre)clinical development. However, due to the enormous costs of clinical trials, additional information regarding the evaluation of novel drug candidates is of high interest, *e.g.* knowledge of the spatially-resolved (<100 μm) drug accumulation in the target tissue. In case the compound of interest contains a non-physiological heteroatom (such as Pt), visualization thereof can be accomplished using micro-X-ray fluorescence ($\mu\text{-XRF}$)¹⁴ or laser ablation (LA) hyphenated to ICP-MS (LA-ICP-MS).^{15–18} LA-ICP-MS combines fast sample preparation, visualization of elemental distributions independent of the chemical binding partner and highly sensitive quantification in the sub $\mu\text{g g}^{-1}$ order in thin tissue sections.^{16,19} It has become of great interest in cancer research and diagnosis to detect tumor markers with the help of metal-labelled antibodies^{20,21} and to identify possible protein binding partners of metallodrugs after 2D gel electrophoresis.^{22,23} However, there are only a few reports on the applications of LA-ICP-MS as imaging tool for metal-based anticancer agents in biological tissue samples. Herewith, the effect of cisplatin-treatment on mice kidneys, testis and cochlea^{24–26} as well as platinum accumulation in tumors of rats after hyperthermic treatment with oxaliplatin have been investigated.²⁷ In addition, the quantitative platinum and ruthenium distribution of cisplatin and the investigational ruthenium complex NKP1339 in different tissues of mice have been compared using LA-ICP-MS.²⁸ Combined imaging techniques of LA-ICP-MS and matrix-assisted laser desorption/ionisation-mass spectrometry (MALDI-MS) have been applied to analyze patient samples from peritoneal carcinosis treated intraperitoneally with cisplatin or oxaliplatin.²⁹

We have recently reported the *in vivo* anticancer activity of three novel platinum(IV)-based drug candidates in the colon cancer model CT-26 together with the average platinum levels in different mice tissues and serum upon treatment.^{30,31} However, in these studies the impact of tumor heterogeneity (*e.g.* varying degrees of vascularization and necrotic areas) as well as drug distribution between malignant and adjacent benign tissue at the microscopic level was not considered. Thus, within this paper we assessed the spatially-resolved platinum distributions of compounds **1–3** (Fig. 1) in tumor and kidney tissue in comparison with satraplatin and oxaliplatin by means of LA-ICP-MS. The obtained data were compared with histological evaluations as well as total platinum levels measured using ICP-MS. To the best of our knowledge, this is the first report on quantitative spatially-resolved platinum biodistribution using LA-ICP-MS in an *in vivo* tumor model upon treatment with platinum(IV)-based anticancer agents.

Experimental

Chemicals

The synthesis and characterization of compounds **1**, **2** and **3** was described previously.^{31–33} Satraplatin was synthesized according to the method given in ref. 34; oxaliplatin was prepared using standard literature methods as described in ref. 35. Milli-Q water (18.2 MΩ cm, Milli-Q Advantage, Darmstadt, Germany) was used for all dilutions for ICP-MS measurements. Nitric acid (65%, p.a., Fluka, Buchs, Switzerland) was further purified in a quartz sub-boiling point distillation unit (Milestone-MLS GmbH, Leutkirch, Germany) before usage. Platinum and rhenium standards for ICP-MS measurements were derived from CPI International (Amsterdam, The Netherlands). Tissue-Tek medium (Sakura Finetek, The Netherlands) was used for embedding of the cryosections. All other reagents and solvents were obtained from commercial sources and were used without further purification.

Animal experiments

Animal experiments were approved by the local ethics commission and were carried out according to the Austrian and FELASA guidelines for animal care and protection. Six- to eight-week-old Balb/c mice were purchased from Harlan Laboratories (San Pietro al Natisone, Italy). The animals were kept in a pathogen-free environment and every procedure was carried out in a laminar airflow cabinet. Murine CT-26 cells (5×10^5) were injected subcutaneously into the right flank and therapy was started when tumor nodules were palpable (day 4). Mice were treated with the compounds at days 4, 7, 11, and 14 using the regimens summarized in Table S1 (ESI[†]). Animals were controlled for distress development every day and tumor size was assessed regularly by caliper measurements. Mice were anesthetized on day 15 approx. 24 h after the last drug application and organs were collected and stored at -20°C for quantitative platinum determination using solution-based ICP-MS. For LA-ICP-MS measurements, the tumor and kidney of one representative mouse were collected, immediately shock-frozen in liquid nitrogen and kept at -80°C until analysis.

Sample preparation for LA-ICP-MS, apoptosis counting and histological evaluation

For LA-ICP-MS measurements, the tumor and kidney samples were embedded in Tissue-Tek medium and cryosectioned into slices of 20 μm thickness using a cryotome (Microm

HM 550, Thermo Fischer). The cryosections were placed onto glass slides, air-dried and kept at room temperature until analysis. A consecutive cryoslice of 5 μm of the respective organ was stained with haematoxylin–eosin (H&E) using standard protocols. Histological evaluation was performed on an Olympus BH2 standard light microscope. In addition, another part of the tumor/kidney was paraffin-embedded, sliced and H&E-stained using routine histological methods for apoptosis counting.

Microwave-assisted digestion of tissue samples and solution-based ICP-MS measurements

Digestion of tissue samples (approx. 10–30 mg) was performed with sub-boiled nitric acid using a microwave system Discover SP-D (CEM Microwave Technology, Germany). The following microwave parameters were used: temperature: 200 °C; ramp time: 4 min; hold time: 6 min; maximal power: 300 W. Digested samples were diluted with Milli-Q water resulting in nitric acid concentrations lower than 3% and platinum concentrations lower than 20 ng g⁻¹. The total platinum content was determined using an ICP-quadrupole MS instrument Agilent 7500ce (Agilent Technologies, Waldbronn, Germany). The ICP-MS instrument was equipped with a CETAC ASX-520 autosampler (Nebraska, USA) and a MicroMist nebulizer at a sample uptake rate of approx. 0.25 ml min⁻¹. The instrument was tuned daily in order to achieve maximum sensitivity. Rhenium served as the internal standard for platinum to account for instrumental fluctuations and matrix effects. The ICP-MS was equipped with nickel cones and operated at an RF power of 1550 W. Argon was used as the plasma gas (15 l min⁻¹) and as a carrier gas with a flow rate of ~1.1 l min⁻¹. The dwell time was set to 0.1 s and the measurement was performed in 10 replicates. The Agilent MassHunter software package (Workstation Software, Version B.01.01, 2012) was used for data processing.

Quantitative bioimaging in tissue samples using LA-ICP-MS

Bioimaging with LA-ICP-MS, including quantification, was performed according to a previously described procedure with slight modification, using matrix-matched calibration standards.²⁸ For this purpose, commercially available pig liver was homogenized (homogenizer, Minilys, Peqlab, USA) and spiked with liquid platinum standards yielding platinum concentrations between 1 and 30 $\mu\text{g g}^{-1}$. The final platinum concentrations of the calibration standards were validated by ICP-MS measurements after microwave-assisted acid digestion using the same conditions as for the organs. Standards were run at the beginning and at the end of the laser experiment, and additionally in the middle when ablation time exceeded two hours in order to monitor instrumental drift.

A Nd:YAG solid state laser (NWR 213, ESI, Fremont, CA, USA) at a wavelength of 213 nm was used to obtain the spatially-resolved distribution of platinum in tumor and kidney sections. The laser beam path was equipped with a square-shaped laser spot table ensuring a constant delivery of energy onto the moving sample throughout the entire diameter of the laser beam. An optical sample map of the region of interest was generated prior to the measurement. The output laser energy was tuned daily in order to ensure complete ablation of the sample material. Ablation was performed at 10 Hz using parallel line scans, a spot size of 70 μm , scan speed of 40 $\mu\text{m s}^{-1}$ and spacing of 10 μm between the lines. The energy

of the laser was increased to reach the substrate (= complete ablation) latest upon 10 shots (corresponding to a movement of the sample stage of approx. half the laser diameter). Assessment of complete ablation was evaluated upon termination of the sequence using an optical microscope. The resulting sample energy was in the range of 0.13–0.16 mJ corresponding to a fluence between 2.7 and 3.2 J cm⁻². The ablated sample material was transferred to the ICP-MS instrument with helium (quality 5.0) at a flow rate of 400 ml min⁻¹. The warm-up time of the laser was set to 10 s and the wash-out delay to 10 s. Laser ablation data was recorded using a Triple Quadrupole ICP-MS Agilent 8800 (Agilent Technologies, Tokyo, Japan) and processed using the Agilent MassHunter software package (Workstation Software, Version B.01.03, 2013). The instrumental parameters for LA-ICP-MS are given in Table 1.

The assessment of average platinum concentrations at the microscopic level by means of LA-ICP-MS was based on a greyscale color scheme for image export in Iolite, providing a linear correlation between the grey value and the registered counts per second (CPS) of the isotope ¹⁹⁵Pt. The CPS were correlated with the concentration of the ablated standards enabling conversion of grey values to concentrations (expressed in µg g⁻¹) using ImageJ (Version 1.48v).³⁸ Upon calibration, the average platinum concentrations were read out using the histogram function of ImageJ.

The software Igor Pro (Wavemetrics, Igor Pro 6.34A) together with its add-on Iolite (Iolite Version 2.5) was used for further data processing and generation of platinum distribution maps.³⁶ The data reduction scheme ‘Trace_Elements’ including blank subtraction and no smoothing of the visualization was applied according to the manual by the authors (Iolite User Manual, Version 2.0).³⁷ The aspect ratio of the image was set according to the dimensions of the ablated area in order to obtain accurately shaped pictures. In case matrix-matched standards were measured for quantitative bioimaging, the platinum concentration of each standard was assigned in the scale bar of the image to the corresponding average counts. If not otherwise stated, the thresholds in the color bar were set to 0 and a platinum concentration of approx. 1.8 µg g⁻¹ for all visualizations in order to facilitate comparison of the platinum amounts between the images solely by the color. In addition, the average platinum concentration (determined by ICP-MS after microwave-assisted digestion) in tissue originating from the same sample, is marked with an asterisk to prove the validity of the obtained quantitative imaging results (Fig. 2).

Results and discussion

Average platinum levels in tumor and kidney sections

The murine colon carcinoma CT-26 model was recently used to assess the *in vivo* anticancer activity and pharmacokinetics of compounds **1–3** in comparison with satraplatin and oxaliplatin.^{30,31} For this purpose, CT-26-bearing mice (*n* = 4) were treated four times (on days 4, 7, 11, and 14) with the respective drugs. The dosages and routes of administration are summarized in detail in Table S1 (ESI[†]). Concentrations were chosen equimolar to satraplatin or equimolar to each other for better comparison of the platinum accumulation in tissue. In the case of compound **3**, the dose exhibiting activity on the leukemia model L1210 was administered,³¹ whereas oxaliplatin-treated mice received the maximal tolerable dose.

39 Twenty-four hours after the last drug application, the mice were sacrificed and tissue samples were collected. The average platinum concentrations in tumor and several organs (including kidney, liver, lung; determined by ICP-MS) have recently been published^{30,31} and are summarized in Table S1 (ESI[†]). Table 2 shows the average platinum levels of the tumor and kidney samples of the individuals used for the here presented study. In all cases, a representative animal was chosen for LA-ICP-MS bioimaging, which did not differ more than 25% and 30% in the case of tumor and renal platinum content, respectively, from the previously reported mean values. Consequently, in accordance with recently published data,^{30,31} the rank of the platinum concentrations in tumor and kidney increased in the following order: compound **2** < satraplatin < oxaliplatin < compound **1** (i.p. and p.o.) < compound **3**.

In order to obtain quantitative information using LA-ICP-MS, matrix-matched standards (consisting of pig liver, spiked with liquid platinum standard solutions) were prepared for calibration.²⁸ The experimentally determined platinum concentrations of the standards were used to plot calibration curves yielding in all cases correlation coefficients >0.99 (for example see Fig. S1, ESI[†]).

Platinum distribution in tumor sections using LA-ICP-MS

The platinum distribution in the CT-26 tumors after treatment with the respective platinum compounds was determined at the microscopic level using LA-ICP-MS (Fig. 2) and correlated with the local tissue histology (visualized by H&E stain of a consecutive slide) as well as the previously determined average platinum content of the tumors. For the LA-ICP-MS experiments, the upper threshold of the intensity bars of all visualizations was scaled to platinum concentrations of $\sim 1.8 \mu\text{g g}^{-1}$, with the exception of compound **3** (Fig. 2E) which was scaled to $\sim 8.2 \mu\text{g g}^{-1}$. In general, the LA-ICP-MS data were in good agreement with the average platinum content assessed previously using ICP-MS (indicated by an asterisk inserted into the color legend).

The detailed measurements using LA-ICP-MS revealed that due to morphological heterogeneity of the tumor sections, the average platinum concentration and the spatially-resolved platinum distribution pattern differed. Thus, although the majority of the ablated sample area exhibited a relatively homogeneous platinum distribution, larger islets of increased platinum levels (indicated by red color) could also be observed in all tumor sections. The following causes for this finding have to be considered: (1) artifacts resulting from the sample preparation (*e.g.* tissue compressions or duplicates) (2) heterogeneity of tumor tissue (*e.g.* due to varying degrees of necrosis/apoptosis, vascularization or susceptibility to the applied drug) (3) non-tumor tissue originating from the treated animal (*e.g.* connective tissue, muscle tissue). In order to further enlighten the nature of these regions, a combined interpretation of greyscaled images taken prior to ablation of the tissue samples and of H&E-stained consecutive tissue sections was conducted. In addition, ablation of ^{13}C was used as an indication for varying degrees of organic matter to rule out artifacts originating from different tissue types. A representative ^{13}C image (compound **1**, corresponding to Fig. 2A) showed a homogeneous distribution of organic matter over the whole tumor tissue (Fig. S2, ESI[†]).

In detail, compound **1** (dosed orally; Fig. 2A) exhibited areas of platinum enrichment corresponding to loose soft tissue sparsely infiltrated by tumor cells and striated muscle from the treated mouse. The adjacent regions, which accumulated platinum to a lesser extent, could be assigned to more solid areas of the tumor. According to the analysis using LA-ICP-MS, the tumor itself accumulated platinum at concentrations of approx. $0.5\text{--}1.2\text{ }\mu\text{g g}^{-1}$, whereas loose soft tissue exhibited increased platinum levels of around $2.0\text{--}3.5\text{ }\mu\text{g g}^{-1}$ (Fig. 3, top; dotted regions). The average platinum concentration of this sample was $\sim 1.7\text{ }\mu\text{g g}^{-1}$ (Table 2), indicating that the platinum enrichment in the non-malignant tumor areas also distinctly affects quantitative measurements of total organ levels. The ablated sample after intraperitoneal administration of compound **1** (Fig. 2C) revealed solely unstructured tumor tissue containing platinum levels of $\sim 1.4\text{ }\mu\text{g g}^{-1}$. This is in accordance with the average platinum concentration ($\sim 1.3\text{ }\mu\text{g g}^{-1}$, Table 2) analyzed using ICP-MS. An overestimation of the tumor-specific platinum levels determined using ICP-MS was also found in other investigated platinum(IV) samples. Compound **2** (Fig. 2D and Fig. S3, middle, ESI†) exhibited a similar platinum accumulation profile to compound **1** after p.o. administration. Increased platinum amounts could be observed in areas of soft tissue with a lower density of infiltrating tumor cells, most probably corresponding to host tissue (approx. $0.7\text{--}1.5\text{ }\mu\text{g g}^{-1}$) surrounding the tumor and lower, but relatively homogeneously distributed platinum levels in tumor tissue ($\sim 0.1\text{--}0.3\text{ }\mu\text{g g}^{-1}$). The administered platinum amount upon intraperitoneal treatment with compound **3** was around 4.5-times higher than for compounds **1** and **2**, which resulted in higher platinum accumulation in the tumor (Fig. 2E and Fig. S3, bottom, ESI†). The tissue section exhibited areas of distinctly different platinum amounts ranging from ~ 1.2 to $\sim 8.2\text{ }\mu\text{g g}^{-1}$. Most parts of the ablated sample area showed platinum concentrations between 4.5 and $5\text{ }\mu\text{g g}^{-1}$, whereas areas with elevated platinum levels of $\sim 8\text{ }\mu\text{g g}^{-1}$ (indicated by red color) could also be found.

For comparison, mice were treated orally with satraplatin (Fig. 2B) and intravenously with oxaliplatin (Fig. 2F), which corresponds to the respective clinically-relevant administration route. In contrast to the experimental compounds, increased platinum levels could be detected not only in areas of loose non-malignant soft tissue but also in some areas of tumor tissue (Fig. 3, bottom and Fig. S3, top, ESI†). For satraplatin, these regions were found mainly at the edge of the tumor with platinum amounts of ~ 1.5 to $1.8\text{ }\mu\text{g g}^{-1}$, whereas the rest of the tumor tissue exhibited platinum levels of $\sim 0.7\text{ }\mu\text{g g}^{-1}$. Treatment with oxaliplatin resulted in a relatively heterogeneous platinum distribution pattern with platinum concentrations ranging from ~ 0.8 to $1.5\text{ }\mu\text{g g}^{-1}$. In these samples, the platinum enrichment (~ 1.0 to $1.5\text{ }\mu\text{g g}^{-1}$) clearly correlated with tumor nodules composed of mitotically active, highly atypical cells as observed in H&E-stained tissue sections (Fig. 3, bottom; dashed lines and Fig. S4, ESI†). Still, platinum was highly concentrated in soft tissue containing a lower density of tumor cells.

In general, areas of (loose) soft tissue within and/or surrounding the tumor comprise increased amounts of platinum. The histologic nature of this tissue (*e.g.* microvessels or connective tissue) is matter of ongoing studies.

As a next step, we addressed the question whether these differences in intratumoral drug distribution correlate with the anticancer activity of the tested platinum drugs. In addition to

the previously published tumor growth throughout the experiment (time-span of two weeks), 30,31 the final tumor weight at day 15 is displayed in Fig. S5 (ESI[†]). Based on the reported tumor growth kinetics, compound **2** and satraplatin were inactive under the experimental conditions used, while compound **1** (administered i.p. or p.o.) showed activity to some extent. On the other hand, oxaliplatin as well as compound **3** exhibited the highest activity of the investigated compounds. In the case of compound **3**, preliminary results of histological evaluations indicated that this activity was based on both apoptosis induction as well as reduction of the mitotic cell population in the malignant tissue (Fig. S6, ESI[†]).

Equimolar dosages of satraplatin and compound **1** as well as of compound **1** and compound **2** (Table 2) were administered p.o. and i.p., respectively, which allows direct comparison of their spatially-resolved platinum distribution in tumor tissue.

In the case of compound **2** (Fig. 2D), the comparison of the laser image with the histological stains showed that the platinum influx seemed to be restricted mainly to peritumoral (connective) tissue with elevated platinum levels of ~ 0.7 to $1.5 \mu\text{g g}^{-1}$. In cancerous tissue only lower amounts of platinum (~ 0.1 to $0.3 \mu\text{g g}^{-1}$) could be detected. These findings could be an explanation for the lack of anticancer activity of this compound for the CT-26 model. In contrast, compound **1** (Fig. 2C) administered at an equimolar dose to compound **2** (Fig. 2D) deeply penetrates into the malignant tissue, probably explaining its activity.

The third generation platinum(II)-based anticancer drug oxaliplatin is part of the standard therapeutic strategy against colon cancer in clinics and was therefore used as the positive control in our study.^{40,41} In addition, we compared it with compound **3**, a platinum(IV) prodrug that is expected to form identical active metabolites like oxaliplatin.³¹ Both compounds were active in the CT-26 tumor model and accumulated not only in soft tissue surrounding the tumor but also penetrated and accumulated in tumor tissue. However, due to varying dosages and routes of administration between oxaliplatin and compound **3**, their concentrations in tissue cannot be compared in our study. Our data show that LA-ICP-MS seems to be a promising tool to better investigate and understand the response of tumor models to metal-based anticancer drug treatment.

So far, only a few reports have been published, dealing with metal-based anticancer drug uptake (cisplatin and oxaliplatin) in tumor tissues and their visualization by LA-ICP-MS.^{27,29} Both studies aimed to investigate the treatment of peritoneal carcinosis by hyperthermic intraperitoneal chemotherapy. Thus, mass spectrometry was used to study the penetration depth of the applied platinum-based drugs in tumor tissue of rat²⁷ or human samples²⁹ up to a treatment time of 60 min. In these investigations, the platinum influx was restricted mainly to the tumor periphery which is a logical consequence of the direct contact of the tumor tissue with the highly-concentrated perfusion solution.^{27,29} In the experiments performed here, in contrast, drug transport to the tumor tissue has to be considered as exclusively *via* the bloodstream, as it is the case for the vast majority of anticancer treatment regimens in clinics. Additionally, we applied repetitive treatments over a time-span of two weeks to gain deeper information on drug response in preclinical *in vivo* experiments. The extent of drug penetration into cancerous tissue in correlation with the anticancer activity can be of importance to estimate the potential of novel metal-based anticancer drug

candidates, but cannot be assessed solely by microwave-assisted digestion and ICP-MS analysis. Spatially-resolved information on the platinum distribution revealed differences compared to the total platinum content in tumor tissue for some of the analyzed compounds. Consequently, we have demonstrated that LA-ICP-MS analysis is capable of determining platinum levels located specifically in the malignant parts of the tumor tissue.

Platinum distribution in kidney sections using LA-ICP-MS

In addition to the tumor samples, the platinum distribution in kidneys was also investigated. This is of interest for metal-based anticancer drugs, as cisplatin treatment (which is routinely employed in half of the standard oncological treatment regimens in clinics)⁹ is frequently associated with nephrotoxicity (one out of three patients).⁴² In order to better understand the mechanisms involved in cisplatin-induced nephrotoxicity, several LA-ICP-MS studies have already focused on platinum imaging in murine kidney sections upon treatment with cisplatin.^{24–26,28} However, there are so far no LA-ICP-MS investigations on the renal distribution of other platinum-based drugs like *e.g.* oxaliplatin and satraplatin. This is especially of interest, as nephrotoxicity has not been observed as major adverse effect for these two compounds during preclinical evaluation and/or in treatment regimens in clinics.^{8,43,44} Consequently, in order to assess whether the renal platinum distribution of oxaliplatin (9 mg kg⁻¹, i.v.) and satraplatin (40 mg kg⁻¹, p.o.) differed from the published data on cisplatin, platinum accumulation maps were obtained using LA-ICP-MS (Fig. 4). The upper threshold in the color code bar was set to a platinum concentration of ~5.2 µg g⁻¹ for oxaliplatin and ~4.2 µg g⁻¹ for satraplatin. In general, both compounds exhibited 8- to 10-times higher platinum levels in the cortex and corticomedullary region than in the medulla of the kidney. The higher platinum accumulation in these regions is in good correlation with the LA-ICP-MS studies in the renal sections of cisplatin-treated rats and mice.^{24–26,28} However, in contrast to the obvious signs of nephrotoxicity observed in the cisplatin samples,^{24–26,28} no signs of cell damage such as tubular necrosis was observed in H&E-stained samples of the animals, tested in this study (Fig. S7, ESI†). Together with a recent report on mice treated with the clinically-tested ruthenium compound KP1339, where no correlation between the ruthenium distribution in renal tissue and nephrotoxicity was found,²⁸ this raises the question of whether LA-ICP-MS is an appropriate tool for the indication of toxic kidney damage. More detailed knowledge on the structure and toxicity of the species (intact parent compound and/or metabolites) present in renal tissue is required. Consequently, drawing conclusions about the possible renal toxicity of platinum-based drug treatment solely based on the quantitative platinum accumulation pattern might not be appropriate. Thus, during preclinical evaluation the assessment of indicative blood serum parameters are still needed in order to estimate the nephrotoxic potential of investigational metal-based anticancer drug candidates.

Conclusions

A quantitative bioimaging method using LA-ICP-MS was successfully applied to the tumor and kidney sections of CT-26-bearing mice upon treatment with platinum-based chemotherapeutics to compare spatially-resolved drug accumulation with histological structures. The platinum distribution maps of tumor samples (originating from six mice)

obtained by LA-ICP-MS correlated with the histological pictures, which allowed discerning the platinum localization in cancerous and nonmalignant tissue. Interestingly, (loose) soft tissue (*e.g.* connective tissue or microvessels) exhibited higher platinum contents than the malignant parts, especially for the experimental compounds. Tumor heterogeneity observed histologically was reflected in the obtained platinum distributions as well. This information is lost in case drug accumulation is studied solely by determination of total platinum tissue levels *e.g.* using ICPMS analysis. Thus, histologically assigned quantitative data on drug uptake could contribute to a better understanding on the efficacy of metal-based antitumor compounds at an early preclinical stage. Therefore, knowledge of the spatially-resolved metal distribution in tumor tissue could become an essential part in the lead compound selection for further metal-based anticancer drug development.

In addition, this study addressed the local platinum distribution in kidneys of treated animals. Oxaliplatin and satraplatin exhibited higher platinum levels in the cortex of kidneys than in the medulla, a pattern which was also observed previously in the case of cisplatin. In contrast to cisplatin, the compounds included in our study have not been shown to induce nephrotoxicity, to the best of our knowledge. This indicates that predictions on the possible renal toxicity of platinum-based drug treatment solely based on the quantitative platinum accumulation pattern might not be appropriate.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We are thankful to G. Zeitler for animal care and Anita Brandstetter for support with the histological evaluations. We acknowledge Luca Bamonti for proof-reading this paper. This work was supported by the Austrian Science Fund grant P26603 (to P.H.). This work was performed in the surroundings of COST action CM1105.

References

1. Kelland LR. *Nat Rev Cancer*. 2007; 7:573–584. [PubMed: 17625587]
2. Hambley TW. *Dalton Trans*. 2007:4929–4937. [PubMed: 17992277]
3. Galanski M, Arion VB, Jakupec MA, Keppler BK. *Curr Pharm Des*. 2003; 9:2078–2089. [PubMed: 14529417]
4. van Rijt SH, Sadler PJ. *Drug Discovery Today*. 2009; 14:1089–1097. [PubMed: 19782150]
5. Gibson D. *Dalton Trans*. 2009:10681–10689. [PubMed: 20023895]
6. Wexselblatt E, Gibson D. *J Inorg Biochem*. 2012; 117:220–229. [PubMed: 22877926]
7. Hall MD, Hambley TW. *Coord Chem Rev*. 2002; 232:49–67.
8. Choy H, Park C, Yao M. *Clin Cancer Res*. 2008; 14:1633–1638. [PubMed: 18347164]
9. Wheate NJ, Walker S, Craig GE, Oun R. *Dalton Trans*. 2010; 39:8113–8127. [PubMed: 20593091]
10. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabro F, James N, Bodrogi I, et al. *J Clin Oncol*. 2009; 27:5431–5438. [PubMed: 19805692]
11. Varma MVS, Radi ZA, Rotter CJ, Litchfield J, El-Kattan AF, Lyubimov AV. *Encyclopedia of Drug Metabolism and Interactions*. John Wiley & Sons, Inc; 2011.
12. Wallace GC, Ramsden DB, Grant HM. *Encyclopedia of Drug Metabolism and Interactions*. John Wiley & Sons, Inc; 2012.

13. Gammelgaard B, Stürup S, Møller C, Lyubimov AV. Encyclopedia of Drug Metabolism and Interactions. John Wiley & Sons, Inc; 2011.
14. West M, Ellis AT, Potts PJ, Strelcić C, Vanhoof C, Węgrzynek D, Wobrowski P. J Anal At Spectrom. 2012; 27:1603–1644.
15. Becker JS, Jakubowski N. Chem Soc Rev. 2009; 38:1969–1983. [PubMed: 19551177]
16. Becker JS, Zoriy M, Matusch A, Wu B, Salber D, Palm C, Becker JS. Mass Spectrom Rev. 2010; 29:156–175. [PubMed: 19557838]
17. Konz I, Fern B, Fernández B, Fernández M, Pereiro R, Sanz-Medel A. Anal Bioanal Chem. 2012; 403:2113–2125. [PubMed: 22543715]
18. Becker JS, Matusch A, Wu B. Anal Chim Acta. 2014; 835:1–18. [PubMed: 24952624]
19. Drescher D, Giesen C, Traub H, Panne U, Kneipp J, Jakubowski N. Anal Chem. 2012; 84:9684–9688. [PubMed: 23121624]
20. Giesen C, Mairinger T, Khoury L, Waentig L, Jakubowski N, Panne U. Anal Chem. 2011; 83:8177–8183. [PubMed: 21923169]
21. Seuma J, Bunch J, Cox A, McLeod C, Bell J, Murray C. Proteomics. 2008; 8:3775–3784. [PubMed: 18712769]
22. Moreno-Gordaliza E, Esteban-Fernandez D, Giesen C, Lehmann K, Lazaro A, Tejedor A, Scheler C, Canas B, Varbanov HP, Valiahdi SM, Kowol CR, et al. J Anal At Spectrom. 2012; 27:1474–1483.
23. Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ. Int J Oncol. 2006; 29:261–268. [PubMed: 16773208]
24. Zoriy M, Matusch A, Spruss T, Becker JS. Int J Mass Spectrom. 2007; 260:102–106.
25. Moreno-Gordaliza E, Giesen C, Lázaro A, Esteban-Fernández D, Humanes B, Cañas B, Panne U, Tejedor A, Jakubowski N, Gómez-Gómez MM. Anal Chem. 2011; 83:7933–7940. [PubMed: 21913725]
26. Reifschneider O, Wehe CA, Raj I, Ehmcke J, Ciarimboli G, Sperling M, Karst U. Metallomics. 2013; 5:1440–1447. [PubMed: 23934158]
27. Gholap D, Verhulst J, Ceelen W, Vanhaecke F. Anal Bioanal Chem. 2012; 402:2121–2129. [PubMed: 22252654]
28. Egger AE, Theiner S, Kornauth C, Heffeter P, Berger W, Keppler BK, Hartinger C. Metallomics. 2014; 6:1616–1625. [PubMed: 24823867]
29. Bianga J, Bouslimani A, Bec N, Quenet F, Mounicou S, Szpunar J, Bouyssiere B, Lobinski R, Larroque C. Metallomics. 2014; 6:1382–1386. [PubMed: 24984817]
30. Theiner S, Varbanov H, Galanski M, Egger A, Berger W, Heffeter P, Keppler BK. J Biol Inorg Chem. 2015; 20:89–99. [PubMed: 25413442]
31. Varbanov HP, Göschl S, Heffeter P, Theiner S, Roller A, Jensen F, Jakupec MA, Berger W, Galanski M, Keppler BK. J Med Chem. 2014; 57:6751–6764. [PubMed: 25032896]
32. Varbanov H, Valiahdi SM, Legin AA, Jakupec MA, Roller A, Galanski M, Keppler BK. Eur J Med Chem. 2011; 46:5456–5464. [PubMed: 21940073]
33. Varbanov HP, Valiahdi SM, Kowol CR, Jakupec MA, Galanski M, Keppler BK. Dalton Trans. 2012; 41:14404–14415. [PubMed: 22886297]
34. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, Bossard GE, Higgins JD. Inorg Chem. 1995; 34:1015–1021. [PubMed: 20000850]
35. Habala L, Galanski M, Yasemi A, Nazarov AA, von Keyserlingk NG, Keppler BK. Eur J Med Chem. 2005; 40:1149–1155. [PubMed: 16040163]
36. Paton C, Hellstrom J, Paul B, Woodhead J, Hergt J. J Anal At Spectrom. 2011; 26:2508–2518.
37. <http://www.iolite.org.au/Iolite.html>.
38. <http://imageJ.nih.gov/ij/>.
39. Jungwirth U, Xanthos DN, Gojo J, Bytzeck AK, Koerner W, Heffeter P, Abramkin S, Jakupec MA, Hartinger CG, Windberger U, Galanski M, et al. Mol Pharmacol. 2012; 81:719–728. [PubMed: 22331606]
40. Akhtar R, Chandel S, Sarotra P, Medhi B. J Gastrointest Oncol. 2014; 6:177–183.

41. Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. J Clin Oncol. 2011; 29:3768–3774. [PubMed: 21859995]
42. Yao X, Panichpisal K, Kurtzman N, Kenneth N. Am J Med Sci. 2007; 334:115–124. [PubMed: 17700201]
43. Armstrong AJ, George DJ. Ther Clin Risk Manage. 2007; 3:877–883.
44. Cassidy J, Misset J-L. Semin Oncol. 2002; 29:11–20.

Fig. 1.

Structural formulae of platinum complexes under investigation; compound **1** ((OC-6-33)-dichloridobis((4-ethoxy)-4-oxobutanoato)-bis(ethylamine)platinum(IV)), compound **2** ((OC-6-33)-diammine(cyclo-butane-1,1-dicarboxylato)bis((4-cyclopentylamino)-4-oxobutanoato)platinum(IV)), compound **3** ((OC-6-22)-((1*R*,2*R*)-diaminocyclohexane)bis(malonato)-platinum(IV)), satraplatin ((OC-6-43)-bis(acetato)amminedichlorido(cyclohexylamine)platinum(IV)) and oxaliplatin ((1*R*,2*R*)-cyclohexane-1,2-diamine)-(ethanedioato-O,O')platinum(II).

Fig. 2.

Platinum distribution in CT-26 tumor sections measured by LA-ICP-MS. Mice were treated with equimolar doses of (A) compound **1** (51.7 mg kg^{-1} , p.o.) or (B) satraplatin (40 mg kg^{-1} , p.o.), (C) compound **1** (8.5 mg kg^{-1} , i.p.) or (D) compound **2** (10 mg kg^{-1} , i.p.); with (E) compound **3** (30 mg kg^{-1} , i.p.) or (F) oxaliplatin (9 mg kg^{-1} , i.v.) on days 4, 7, 11, and 14. For LA-ICP-MS measurements cryosections were used. In addition, a consecutive H&E-stained cryosection is shown for comparison. The asterisks within the intensity bars

correspond to the average platinum concentration determined using ICP-MS after microwave-assisted digestion.

Fig. 3.

Detailed view of ablated tumor samples after treatment with compound **1** (p.o., top) and oxaliplatin (i.v., bottom); laser platinum image (left), sample map taken prior to laser ablation (middle) and H&E-stained section (right). The dotted spots in the H&E-stained slides correspond to loose connective tissue with sparsely scattered tumor cells. The dashed lines indicate areas of necrotic tissue within the tumor nodule.

Fig. 4.

Distribution of platinum in kidney sections of CT-26-bearing mice treated either with oxaliplatin (9 mg kg^{-1} , i.v.) (left) or satraplatin (40 mg kg^{-1} , p.o.) (right). A consecutive H&E-stained cryosection is shown for comparison. The asterisks within the intensity bars correspond to the average platinum concentration determined using ICP-MS after the microwave-assisted digestion.

Table 1

Instrumental parameters of LA-ICP-MS

	LA-ICP-MS
RF power [W]	1350
Cone material	Nickel
Carrier gas [l min ⁻¹]	1.1
Make up gas [l min ⁻¹]	—
Plasma gas [l min ⁻¹]	15
Monitored isotopes	¹³ C, ¹⁹⁵ Pt
Dwell time [s]	0.1
Number of replicates	1

Table 2

Average platinum concentrations in tumor and kidney samples of the treated mouse selected for bioimaging using LA-ICP-MS. Values were determined using ICP-MS after microwave-assisted digestion and the results are given as mean $\pm$ standard deviation (samples from one mouse were measured in triplicates). In addition, the average concentration was determined by LA-ICP-MS using the histogram function of ImageJ as described in the Experimental section

Compound	Route of admin.	Pt admin. [$\mu\text{g g}^{-1}$]	Pt concentration [$\mu\text{g g}^{-1}$]		
			Tumor (ICP-MS)	Kidney (ICP-MS)	Tumor (LA-ICP-MS)
Satraplatin	p.o.	15.63	0.70 ± 0.06	2.37 ± 0.18	0.81
1	p.o.	15.63	1.66 ± 0.18	8.54 ± 0.45	0.90
1	i.p.	2.58	1.29 ± 0.24	8.15 ± 0.38	1.18
2	i.p.	2.58	0.72 ± 0.15	2.16 ± 0.56	0.66
3	i.p.	11.04	5.06 ± 0.14	12.78 ± 0.33	4.60
Oxaliplatin	i.v.	4.42	0.96 ± 0.08	4.54 ± 0.17	1.15